Display options
Cite
Tokuda N, Kitaoka Y, Matsuzawa A, et al. The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients. J Ophthalmol. 2015;2015:689076doi: 10.1155/2015/689076.
Tokuda, N., Kitaoka, Y., Matsuzawa, A., Miyamoto, J., Sakae, S., Munemasa, Y., & Takagi, H. (2015). The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients. Journal of ophthalmology, 2015689076. https://doi.org/10.1155/2015/689076
Tokuda, Naoto, et al. "The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients." Journal of ophthalmology vol. 2015 (2015): 689076. doi: https://doi.org/10.1155/2015/689076
Tokuda N, Kitaoka Y, Matsuzawa A, Miyamoto J, Sakae S, Munemasa Y, Takagi H. The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients. J Ophthalmol. 2015;2015:689076. doi: 10.1155/2015/689076. Epub 2015 May 10. PMID: 26064674; PMCID: PMC4441993.
Copy Download .nbib Format: NLM
Share it on

J Ophthalmol. 2015;2015:689076. doi: 10.1155/2015/689076. Epub 2015 May 10.

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients.

Journal of ophthalmology

Naoto Tokuda, Yasushi Kitaoka, Akiko Matsuzawa, Junsuke Miyamoto, Shinsuke Sakae, Yasunari Munemasa, Hitoshi Takagi

Affiliations

  1. Department of Ophthalmology, St. Marianna University School of Medicine, Kanagawa 216-8511, Japan.

PMID: 26064674 PMCID: PMC4441993 DOI: 10.1155/2015/689076

Abstract

Purpose. To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma eye drops. Patients and Methods. Forty eyes of 40 patients receiving latanoprost (0.005%) and timolol (0.5%) were included in this randomized prospective study. The patients were randomly divided into two groups (n = 20): the rebamipide-treated group and control group. Changes in intraocular pressure, tear film break-up time (TBUT), and corneal epithelial barrier function were evaluated at baseline, 4 weeks, and 8 weeks after rebamipide administration. Furthermore, superficial punctate keratopathy severity was evaluated by scoring the lesion area and density. Results. There was no significant difference in intraocular pressure before and after rebamipide treatment. However, corneal epithelial barrier function improved significantly 4 and 8 weeks after rebamipide treatment. TBUT was partially, but significantly, increased (P = 0.02) 8 weeks after rebamipide treatment, whereas no significant change was observed at 4 weeks. Additionally, a significant decrease in area and density of keratopathy was observed 8 weeks after rebamipide treatment but not at 4 weeks. The control group showed no significant difference compared to baseline. Conclusions. Our data suggests that rebamipide treatment may reduce the occurrence of drug-induced ocular surface disorder.

References

  1. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):565-71 - PubMed
  2. Cornea. 2004 Jul;23(5):490-6 - PubMed
  3. J Ocul Pharmacol Ther. 2012 Apr;28(2):123-8 - PubMed
  4. Cornea. 2014 Aug;33(8):806-11 - PubMed
  5. Clin Ophthalmol. 2011;5:517-25 - PubMed
  6. Cornea. 1995 Sep;14(5):485-9 - PubMed
  7. Ophthalmology. 1992 Jul;99(7):1082-8 - PubMed
  8. Dig Dis Sci. 2009 Jul;54(7):1500-7 - PubMed
  9. Br J Ophthalmol. 1993 Sep;77(9):590-6 - PubMed
  10. Ophthalmologica. 2000 Sep-Oct;214(5):332-6 - PubMed
  11. Ophthalmology. 2012 Dec;119(12 ):2471-8 - PubMed
  12. Br J Ophthalmol. 2013 Jul;97(7):912-6 - PubMed
  13. Ophthalmologica. 2002 Sep-Oct;216(5):351-4 - PubMed
  14. J Ophthalmol. 2014;2014:460483 - PubMed
  15. Am J Ophthalmol. 2008 Sep;146(3):350-356 - PubMed
  16. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261-70 - PubMed
  17. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4293-301 - PubMed
  18. Adv Ther. 2008 Aug;25(8):743-51 - PubMed
  19. Invest Ophthalmol Vis Sci. 2012 Aug 03;53(9):5154-60 - PubMed
  20. CLAO J. 1995 Oct;21(4):221-32 - PubMed
  21. Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2572-760 - PubMed
  22. Br J Ophthalmol. 1990 Jul;74(7):409-12 - PubMed
  23. Am J Ophthalmol. 1997 Dec;124(6):723-8 - PubMed
  24. J Glaucoma. 2008 Aug;17(5):350-5 - PubMed
  25. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):597-603 - PubMed
  26. Eur J Pharmacol. 1987 Oct 6;142(1):23-9 - PubMed
  27. Arch Ophthalmol. 2003 Nov;121(11):1537-9 - PubMed
  28. J Ocul Pharmacol Ther. 2012 Jun;28(3):264-70 - PubMed
  29. Cornea. 2010 Jun;29(6):618-21 - PubMed
  30. Acta Ophthalmol (Copenh). 1969;47(4):865-80 - PubMed
  31. Cornea. 2003 Nov;22(8):709-15 - PubMed
  32. Cornea. 2004 Aug;23 (6):613-9 - PubMed
  33. J Glaucoma. 2003 Dec;12(6):486-90 - PubMed

Publication Types